David B. Roberts - 29 Feb 2024 Form 4 Insider Report for LEMAITRE VASCULAR INC (LMAT)

Role
President and Director, Director
Signature
/s/ David C. Hissong
Issuer symbol
LMAT
Transactions as of
29 Feb 2024
Net transactions value
-$13,720
Form type
4
Filing time
04 Mar 2024, 21:03:37 UTC
Previous filing
15 Feb 2024
Next filing
01 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LMAT Common Stock Award $0 +2,649 +16% $0.000000 19,329 29 Feb 2024 Direct F1, F2
transaction LMAT Common Stock Options Exercise $0 +6 +0.03% $0.000000 19,335 29 Feb 2024 Direct F3
transaction LMAT Common Stock Tax liability $13,720 -196 -1% $70.00 19,139 29 Feb 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LMAT Dividend Equivalent Rights Options Exercise $0 -7 -25% $0.000000 20 29 Feb 2024 Common Stock 7 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent LMAT common stock acquired on February 29, 2024, upon settlement of a Performance Share Unit (PSU) award granted on December 12, 2022. The PSU award vests as follows: 25% upon determination by the Compensation Committee and the balance vests in equal annual installments from the grant date over the next three years.
F2 Each PSU represents a contingent right to receive one share of common stock upon vesting based on the attainment of performance goals.
F3 Represents shares acquired upon release of dividend equivalent rights, as reported in Table II, on a one-for-one basis.
F4 These shares represent shares withheld by the issuer to satisfy tax withholding obligations incurred upon the vesting of performance stock units awarded to the reporting person on December 12, 2022. This transaction is considered an exempt sale pursuant to Rule 16b-3(e) promulgated under the Securities Exchange Act of 1934.
F5 These dividend equivalent rights were released in connection with the vesting of a performance share unit (PSU) award granted on December 12, 2022. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.